1932

Abstract

Obesity is a leading modifiable risk factor for the development of several epithelial malignancies. In addition to increasing risk, obesity also confers worse prognosis for many cancers. Obesity represents an overall state of energy imbalance frequently associated with systemic effects including insulin resistance, altered hormone signaling, and high circulating levels of proinflammatory mediators. In addition to its systemic effects, obesity causes subclinical white adipose inflammation including increased tissue levels of proinflammatory mediators. Both local and systemic effects are likely to contribute to the development and progression of cancer. An understanding of the interplay between local and systemic alterations involved in the obesity–cancer link provides the basis for developing interventions aimed at mitigating the protumorigenic effects.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-050913-022228
2015-01-14
2024-04-17
Loading full text...

Full text loading...

/deliver/fulltext/med/66/1/annurev-med-050913-022228.html?itemId=/content/journals/10.1146/annurev-med-050913-022228&mimeType=html&fmt=ahah

Literature Cited

  1. Levi J, Segal LM, St. Laurent R. 1.  et al. 2012. F as in Fat: how obesity threatens America's future 2012 Trust for America's Health Rep. http://healthyamericans.org/report/100/
  2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. 2.  2010. Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–41 [Google Scholar]
  3. Calle EE, Kaaks R. 3.  2004. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4:579–91 [Google Scholar]
  4. van Kruijsdijk RC, van der Wall E, Visseren FL. 4.  2009. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol. Biomark. Prev. 18:2569–78 [Google Scholar]
  5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. 5.  2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348:1625–38 [Google Scholar]
  6. Iyengar NM, Morris PG, Hudis CA, Dannenberg AJ. 6.  2013. Obesity, inflammation, and breast cancer. Obesity, Inflammation, and Cancer AJ Dannenberg, NA Berger 181–217 New York: Springer [Google Scholar]
  7. Yoon HH, Lewis MA, Shi Q. 7.  et al. 2011. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J. Clin. Oncol. 29:4561–67 [Google Scholar]
  8. Iyengar NM, Hudis CA, Dannenberg AJ. 8.  2013. Obesity and inflammation: new insights into breast cancer development and progression. American Society of Clinical Oncology 2013 Educational Book46–51 Alexandria, VA: Am. Soc. Clin. Oncol. [Google Scholar]
  9. Iyengar NM, Kochhar A, Morris PG. 9.  et al. 2014. Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer 120:983–91 [Google Scholar]
  10. Berger NA.10.  2014. Obesity-associated gastrointestinal tract cancer: from beginning to end. Cancer 120:935–39 [Google Scholar]
  11. Guilherme A, Virbasius JV, Puri V, Czech MP. 11.  2008. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9:367–77 [Google Scholar]
  12. Hursting SD, Digiovanni J, Dannenberg AJ. 12.  et al. 2012. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev. Res. 5:1260–72 [Google Scholar]
  13. Xu XJ, Gauthier MS, Hess DT. 13.  et al. 2012. Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue. J. Lipid Res. 53:792–801 [Google Scholar]
  14. Kloting N, Fasshauer M, Dietrich A. 14.  et al. 2010. Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299:E506–15 [Google Scholar]
  15. Denis GV, Obin MS. 15.  2013. “Metabolically healthy obesity”: origins and implications. Mol. Aspects Med. 34:59–70 [Google Scholar]
  16. Chen S, Chen Y, Liu X. 16.  et al. 2014. Insulin resistance and metabolic syndrome in normal-weight individuals. Endocrine 46:496–504 [Google Scholar]
  17. Deepa M, Papita M, Nazir A. 17.  et al. 2014. Lean people with dysglycemia have a worse metabolic profile than centrally obese people without dysglycemia. Diabetes Technol. Ther. 16:91–96 [Google Scholar]
  18. Lee MJ, Wu Y, Fried SK. 18.  2013. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol. Aspects Med. 34:1–11 [Google Scholar]
  19. Park J, Euhus DM, Scherer PE. 19.  2011. Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr. Rev. 32:550–70 [Google Scholar]
  20. Khandekar MJ, Cohen P, Spiegelman BM. 20.  2011. Molecular mechanisms of cancer development in obesity. Nat. Rev. Cancer 11:886–95 [Google Scholar]
  21. Pollak MN, Schernhammer ES, Hankinson SE. 21.  2004. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4:505–18 [Google Scholar]
  22. Goodwin PJ, Ennis M, Pritchard KI. 22.  et al. 2002. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol. 20:42–51 [Google Scholar]
  23. Ma J, Li H, Giovannucci E. 23.  et al. 2008. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 9:1039–47 [Google Scholar]
  24. Barone BB, Yeh HC, Snyder CF. 24.  et al. 2008. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300:2754–64 [Google Scholar]
  25. Wong KK, Engelman JA, Cantley LC. 25.  2010. Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev. 20:87–90 [Google Scholar]
  26. Zoncu R, Efeyan A, Sabatini DM. 26.  2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12:21–35 [Google Scholar]
  27. Lueprasitsakul P, Latour D, Longcope C. 27.  1990. Aromatase activity in human adipose tissue stromal cells: effect of growth factors. Steroids 55:540–44 [Google Scholar]
  28. Rosen ED, Spiegelman BM. 28.  2014. What we talk about when we talk about fat. Cell 156:20–44 [Google Scholar]
  29. Hofbauer KG.29.  2002. Molecular pathways to obesity. Int. J. Obes. Relat. Metab. Disord. 26:Suppl. 2S18–27 [Google Scholar]
  30. Alberti KG, Eckel RH, Grundy SM. 30.  et al. 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–45 [Google Scholar]
  31. Pothiwala P, Jain SK, Yaturu S. 31.  2009. Metabolic syndrome and cancer. Metab. Syndr. Relat. Disord. 7:279–88 [Google Scholar]
  32. Capasso I, Esposito E, Pentimalli F. 32.  et al. 2010. Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol. Ther. 10:1240–43 [Google Scholar]
  33. Porto LA, Lora KJ, Soares JC, Costa LO. 33.  2011. Metabolic syndrome is an independent risk factor for breast cancer. Arch. Gynecol. Obstet. 284:1271–76 [Google Scholar]
  34. Rosato V, Bosetti C, Talamini R. 34.  et al. 2011. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann. Oncol. 22:2687–92 [Google Scholar]
  35. Cleary MP, Grossmann ME. 35.  2009. Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 150:2537–42 [Google Scholar]
  36. Reeves GK, Pirie K, Beral V. 36.  et al. 2007. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335:1134–45 [Google Scholar]
  37. Li CI, Daling JR, Malone KE. 37.  2003. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J. Clin. Oncol. 21:28–34 [Google Scholar]
  38. Key TJ, Appleby PN, Reeves GK. 38.  et al. 2003. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J. Natl. Cancer Inst. 95:1218–26 [Google Scholar]
  39. Lorincz AM, Sukumar S. 39.  2006. Molecular links between obesity and breast cancer. Endocr. Relat. Cancer 13:279–92 [Google Scholar]
  40. Yager JD, Davidson NE. 40.  2006. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354:270–82 [Google Scholar]
  41. Pequeux C, Raymond-Letron I, Blacher S. 41.  et al. 2012. Stromal estrogen receptor-alpha promotes tumor growth by normalizing an increased angiogenesis. Cancer Res. 72:3010–19 [Google Scholar]
  42. Giovannucci E, Rimm EB, Liu Y. 42.  et al. 2003. Body mass index and risk of prostate cancer in U.S. health professionals. J. Natl. Cancer Inst. 95:1240–44 [Google Scholar]
  43. Jayachandran J, Banez LL, Aronson WJ. 43.  et al. 2009. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 115:5263–71 [Google Scholar]
  44. Parker AS, Thiel DD, Bergstralh E. 44.  et al. 2013. Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies. Prostate Cancer Prostatic Dis. 16:352–56 [Google Scholar]
  45. Lonergan PE, Tindall DJ. 45.  2011. Androgen receptor signaling in prostate cancer development and progression. J. Carcinog. 10:20 doi: 10.4103/1477-3163.83937 [Google Scholar]
  46. Dhindsa S, Miller MG, McWhirter CL. 46.  et al. 2010. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 33:1186–92 [Google Scholar]
  47. Tilg H, Moschen AR. 47.  2006. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6:772–83 [Google Scholar]
  48. Housa D, Housova J, Vernerova Z, Haluzik M. 48.  2006. Adipocytokines and cancer. Physiol. Res. 55:233–44 [Google Scholar]
  49. Bub JD, Miyazaki T, Iwamoto Y. 49.  2006. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem. Biophys. Res. Commun. 340:1158–66 [Google Scholar]
  50. Kim AY, Lee YS, Kim KH. 50.  et al. 2010. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol. Endocrinol. 24:1441–52 [Google Scholar]
  51. Cong L, Gasser J, Zhao J. 51.  et al. 2007. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2. Endocr. Relat. Cancer 14:713–20 [Google Scholar]
  52. Grossmann ME, Nkhata KJ, Mizuno NK. 52.  et al. 2008. Effects of adiponectin on breast cancer cell growth and signaling. Br. J. Cancer 98:370–79 [Google Scholar]
  53. Sharma D, Wang J, Fu PP. 53.  et al. 2010. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 52:1713–22 [Google Scholar]
  54. Fogarty S, Hardie DG. 54.  2010. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim. Biophys. Acta 1804:581–91 [Google Scholar]
  55. Lam JBB, Chow KHM, Xu A. 55.  et al. 2009. Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities. PLOS ONE 4:3e4968 [Google Scholar]
  56. Miyoshi Y, Funahashi T, Kihara S. 56.  et al. 2003. Association of serum adiponectin levels with breast cancer risk. Clin. Cancer Res. 9:5699–704 [Google Scholar]
  57. Duggan C, Irwin ML, Xiao L. 57.  et al. 2011. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J. Clin. Oncol. 29:32–39 [Google Scholar]
  58. Mantzoros C, Petridou E, Dessypris N. 58.  et al. 2004. Adiponectin and breast cancer risk. J. Clin. Endocrinol. Metab. 89:1102–7 [Google Scholar]
  59. Soliman PT, Wu D, Tortolero-Luna G. 59.  et al. 2006. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 106:2376–81 [Google Scholar]
  60. Xu XT, Xu Q, Tong JL. 60.  et al. 2011. Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J. Dig. Dis. 12:234–44 [Google Scholar]
  61. Michalakis K, Williams CJ, Mitsiades N. 61.  et al. 2007. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol. Biomark. Prev. 16:308–13 [Google Scholar]
  62. Li H, Stampfer MJ, Mucci L. 62.  et al. 2010. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin. Chem. 56:34–43 [Google Scholar]
  63. Friedman JM, Halaas JL. 63.  1998. Leptin and the regulation of body weight in mammals. Nature 395:763–70 [Google Scholar]
  64. Sharma D, Saxena NK, Vertino PM, Anania FA. 64.  2006. Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr. Relat. Cancer 13:629–40 [Google Scholar]
  65. Choi JH, Park SH, Leung PC, Choi KC. 65.  2005. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J. Clin. Endocrinol. Metab. 90:207–10 [Google Scholar]
  66. Hoda MR, Keely SJ, Bertelsen LS. 66.  et al. 2007. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br. J. Surg. 94:346–54 [Google Scholar]
  67. Onuma M, Bub JD, Rummel TL, Iwamoto Y. 67.  2003. Prostate cancer cell–adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J. Biol. Chem. 278:42660–67 [Google Scholar]
  68. Chia VM, Newcomb PA, Lampe JW. 68.  et al. 2007. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. Cancer Epidemiol. Biomark. Prev. 16:2697–703 [Google Scholar]
  69. Grossmann ME, Mizuno NK, Bonorden MJ. 69.  et al. 2009. Role of the adiponectin leptin ratio in prostate cancer. Oncol. Res. 18:269–77 [Google Scholar]
  70. Olefsky JM, Glass CK. 70.  2010. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72:219–46 [Google Scholar]
  71. Pierce BL, Ballard-Barbash R, Bernstein L. 71.  et al. 2009. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 27:3437–44 [Google Scholar]
  72. Visser M, Bouter LM, McQuillan GM. 72.  et al. 1999. Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131–35 [Google Scholar]
  73. Morris PG, Zhou XK, Milne GL. 73.  et al. 2013. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev. Res. 6:428–36 [Google Scholar]
  74. Kim S, Taylor JA, Milne GL, Sandler DP. 74.  2013. Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women. Cancer Prev. Res. 6:511–18 [Google Scholar]
  75. Amano SU, Cohen JL, Vangala P. 75.  et al. 2014. Local proliferation of macrophages contributes to obesity-associated adipose tissue inflammation. Cell Metab. 19:162–71 [Google Scholar]
  76. Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. 76.  2013. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin. Cancer Res. 19:6074–83 [Google Scholar]
  77. Mantovani A, Allavena P, Sica A, Balkwill F. 77.  2008. Cancer-related inflammation. Nature 454:436–44 [Google Scholar]
  78. Coussens LM, Werb Z. 78.  2002. Inflammation and cancer. Nature 420:860–67 [Google Scholar]
  79. Osborn O, Olefsky JM. 79.  2012. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 18:363–74 [Google Scholar]
  80. Monteiro R, Azevedo I. 80.  2010. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010:1–10 [Google Scholar]
  81. Cinti S, Mitchell G, Barbatelli G. 81.  et al. 2005. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46:2347–55 [Google Scholar]
  82. Subbaramaiah K, Howe LR, Bhardwaj P. 82.  et al. 2011. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev. Res. 4:329–46 [Google Scholar]
  83. Morris PG, Hudis CA, Giri D. 83.  et al. 2011. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev. Res. 4:1021–29 [Google Scholar]
  84. Sun X, Casbas-Hernandez P, Bigelow C. 84.  et al. 2012. Normal breast tissue of obese women is enriched for macrophage markers and macrophage-associated gene expression. Breast Cancer Res. Treat. 131:1003–12 [Google Scholar]
  85. Bachelot T, Ray-Coquard I, Menetrier-Caux C. 85.  et al. 2003. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br. J. Cancer 88:1721–26 [Google Scholar]
  86. Subbaramaiah K, Morris PG, Zhou XK. 86.  et al. 2012. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov. 2:356–65 [Google Scholar]
  87. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. 87.  1996. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739–42 [Google Scholar]
  88. Irahara N, Miyoshi Y, Taguchi T. 88.  et al. 2006. Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer. Int. J. Cancer 118:1915–21 [Google Scholar]
  89. Shapiro H, Pecht T, Shaco-Levy R. 89.  et al. 2013. Adipose tissue foam cells are present in human obesity. J. Clin. Endocrinol. Metab. 98:1173–81 [Google Scholar]
  90. Underhill DM, Goodridge HS. 90.  2012. Information processing during phagocytosis. Nat. Rev. Immunol. 12:492–502 [Google Scholar]
  91. Pendyala S, Walker JM, Holt PR. 91.  2012. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 142:1100–01 [Google Scholar]
  92. Lee JY, Sohn KH, Rhee SH, Hwang D. 92.  2001. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through toll-like receptor 4. J. Biol. Chem. 276:16683–89 [Google Scholar]
  93. Chlebowski RT, Blackburn GL, Thomson CA. 93.  et al. 2006. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J. Natl. Cancer Inst. 98:1767–76 [Google Scholar]
  94. Campbell KL, Foster-Schubert KE, Alfano CM. 94.  et al. 2012. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. J. Clin. Oncol. 30:2314–26 [Google Scholar]
  95. Imayama I, Ulrich CM, Alfano CM. 95.  et al. 2012. Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res. 72:2314–26 [Google Scholar]
  96. Ligibel JA, Goodwin PJ. 96.  2012. NEW and RENEW: building the case for weight loss in breast cancer. J. Clin. Oncol. 30:2294–96 [Google Scholar]
  97. Goodwin PJ, Pritchard KI, Ennis M. 97.  et al. 2008. Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer 8:501–5 [Google Scholar]
  98. Dannenberg AJ, Altorki NK, Boyle JO. 98.  et al. 2001. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2:544–51 [Google Scholar]
  99. Higgins MJ, Prowell TM, Blackford AL. 99.  et al. 2012. A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res. Treat. 131:915–24 [Google Scholar]
  100. Hudis CA, Subbaramaiah K, Morris PG, Dannenberg AJ. 100.  2012. Breast cancer risk reduction: no pain, no gain?. J. Clin. Oncol. 30:3436–38 [Google Scholar]
/content/journals/10.1146/annurev-med-050913-022228
Loading
/content/journals/10.1146/annurev-med-050913-022228
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error